The Vanguard Group filed an amended Schedule 13G reporting beneficial ownership of Eli Lilly (LLY) common stock. As of 09/30/2025, Vanguard reported 80,952,595 shares, representing 8.55% of the class. Vanguard is identified as an investment adviser and certified the holdings were acquired and are held in the ordinary course, not to change or influence control.
The filing details 0 shares with sole voting power and 4,843,238 shares with shared voting power. Vanguard reported 73,223,987 shares with sole dispositive power and 7,728,608 shares with shared dispositive power. The filing also notes that Vanguard’s clients have rights to dividends or sale proceeds, and no single other person’s interest exceeds 5%.
Eli Lilly (LLY) reported sharply higher Q3 results. Revenue rose to $17,600.8 million from $11,439.1 million a year ago, driven by cardiometabolic medicines. Net income increased to $5,582.5 million from $970.3 million, with diluted EPS of $6.21 versus $1.07.
Growth was led by Mounjaro ($6,515.1 million total) and Zepbound ($3,588.1 million), lifting total cardiometabolic health revenue to $13,177.9 million. Oncology contributed $2,407.6 million, and immunology $1,362.4 million. Operating cash flow for the nine months reached $13,588.4 million. Cash and equivalents were $9,791.9 million, while long‑term debt was $40,873.6 million. The company recognized $655.7 million of acquired IPR&D and $364.9 million of special charges in the quarter.
Lilly completed the Verve Therapeutics acquisition for $549.4 million net of cash, with a contingent value right of up to $300.0 million. Pre‑launch inventories were $952.3 million, primarily for orforglipron. As of September 30, $12.40 billion remained under the $15.00 billion share repurchase authorization. Shares outstanding were 945,383,757 as of October 27, 2025.
Eli Lilly and Company furnished an 8-K under Item 2.02 to announce it issued a press release with financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference into Item 2.02.
The information in Item 2.02 is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act. The filing also includes Exhibit 104 for the cover page Inline XBRL. The document identifies Lilly’s listed securities, including common stock (LLY) on the NYSE.
Eli Lilly (LLY) reported an insider transaction by a director on 10/20/2025. The filing shows an acquisition of 6.129 shares of common stock at $808.96 per share, bringing the director’s direct beneficial ownership to 2,728.14 shares.
According to the footnote, the acquired amount was deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person’s separation from service.
Eli Lilly (LLY) director reported a routine equity accrual. On 10/20/2025, the director acquired 18.336 shares of common stock at $808.96 per share, recorded as an “A” (acquisition). Following this transaction, the director beneficially owns 16,474.296 shares, held directly.
The filing notes these shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in common shares after the director’s separation from service.
Eli Lilly (LLY) director Mary Lynne Hedley reported an acquisition of 12.259 shares of common stock on 10/20/2025 at $808.96 per share. The filing states the shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in common stock following her separation from service.
After the transaction, beneficial ownership stood at 2,015.828 shares held directly and 98 shares held indirectly by trust.
Eli Lilly (LLY) director transaction: On 10/20/2025, director J. Erik Fyrwald reported acquiring 12.259 shares at $808.96. The filing notes the director elected to defer cash compensation into stock units under the Lilly Directors' Deferral Plan, to be settled in common shares after separation from service. Following the entry, beneficial ownership stands at 74,763.656 shares, held directly.
Eli Lilly (LLY) director reported acquiring 14.525 shares of common stock on 10/20/2025 at $808.96 per share. The award was deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares following the director’s separation from service. After the transaction, beneficial ownership was 55,151.946 shares directly and 758 shares indirectly by trust.
Eli Lilly (LLY) insider transaction: A reporting person disclosed open‑market sales of Eli Lilly common stock on 10/10/2025. The filer sold 468 shares at a weighted average price of $862.34 (prices ranged from $862.00 to $862.74) and 3,190 shares at a weighted average price of $863.369 (prices ranged from $863.00 to $863.995). Following these transactions, the filer directly owned 94,533,320 shares. The form was signed by Diane M. Stenson, Vice President & Treasurer, on behalf of Lilly Endowment Inc.
Lilly Endowment Inc., a director-related reporting person, sold a total of 10,602 shares of Eli Lilly & Co common stock on 10/09/2025. The Form 4 lists eight separate sale entries with weighted-average prices for each block; the reported trade price ranges span from $848.09 up to $857.26. After these transactions, the reporting person beneficially owns 94,536,978 shares directly. Each sale line notes the reporting person can provide detailed per-price quantities on request, and the Form 4 was signed by Peter A. Buck on behalf of Lilly Endowment Inc.